TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04267887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT03065569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 16 mL of 0.125% bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 16 mL of 0.125% bupivacaine
Study: NCT04267887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02682459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Study: NCT04256174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120 or placebo- Part 1- Cohort 1
Description: Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120 or placebo- Part 1- Cohort 2
Description: Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120 or placebo- Part 1- Cohort 3
Description: Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120 or placebo- Part 1- Cohort 4
Description: Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120 or placebo- Part 1- Cohort 5
Description: Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120 or placebo- Part 2- Cohort 1
Description: Multiple low doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120 or placebo- Part 2- Cohort 2
Description: Multiple medium doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120 or placebo- Part 2- Cohort 3
Description: Multiple high doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120 or placebo- Part 2- Cohort 4
Description: Multiple high doses of AK120 or placebo are administered subcutaneously as a bi-weekly dose for a total of three doses to subjects with moderate-to-severe atopic dermatitis.
Study: NCT04452123

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic argon plasma treatment of endometrioma
Description: Laparoscopic Argon Plasma vaporising the endometriotic cyst lining only until haemosiderin pigment stained tissue is no longer visible

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic argon plasma treatment of endometrioma
Description: Laparoscopic Argon Plasma vaporising the endometriotic cyst lining only until haemosiderin pigment stained tissue is no longer visible

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic stripping of endometrioma and suture/coagulation of the rest of ovary
Description: Laparoscopic dissecting of capsule of endometrioma and achieving hemostasis with suture of rest of the ovary or with gentle coagulation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic stripping of endometrioma and suture/coagulation of the rest of ovary
Description: Laparoscopic dissecting of capsule of endometrioma and achieving hemostasis with suture of rest of the ovary or with gentle coagulation.
Study: NCT01889108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPEEDI
Description: Behavior intervention combining parent education and physical therapy intervention for preterm infants
Study: NCT02837471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiezoRx medical grade pedometer
Description: Participants will be asked to freely use the PiezoRx medical grade pedometer for 12 weeks.~Participants have access to a personal account created online and can record the daily steps count and physical activity.~Participants will receive the standard care by the FrancoForme Cardiovascular rehabilitation and prevention program
Study: NCT03047967

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lung function tests
Description: baby-body plethysmography
Study: NCT00840177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 1.5 g/m2/day given by continuous IV on days 4-7
Study: NCT03047967

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lung function tests
Description: baby-body plethysmography

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nasal brushing
Description: Epithelial sample collecting for in vitro study

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nasal brushing
Description: Epithelial sample collecting for in vitro study
Study: NCT02733822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Study: NCT00355355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talaporfin sodium
Description: LS11 (Talaporfin Sodium) slowly administered (3-5 min.) in a free flowing intravenous drip at a dose of 1 mg/kg.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interstitial Light Emitting Diodes
Description: 200 J/cm per Light Source at 20 mW/cm light energy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous placement of device in the liver
Description: Litx™ treatment group undergo CT or Ultrasound guided percutaneous placement of a single, two, three, or four Light Sources depending on their tumor characteristics. No more than 4 Light Sources will be used at a single treatment. The Light Source(s) may be used in a single lesion or in multiple lesions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: The standard of care could include any one of the following treatment options: Percutaneous Ethanol Injection (PEI), Transcatheter Arterial Chemoembolization (TACE), Radio Frequency Ablation (RFA), Cryotherapy, Systemic Chemotherapy, or other modalities that may be used at a particular institution.
Study: NCT02267291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive positive pressure ventilation
Description: Ventilatory support to alter intrathoracic pressure
Study: NCT02840253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS
Study: NCT01589146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin, Low-Molecular-Weight
Description: 4 weeks heparin prophylaxis
Study: NCT03783962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Intervention - Cooking
Description: Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted and reinforced throughout the program. In-person sessions facilitated by an interventionist provide the group meetings. The program provides 24 weekly facilitated group sessions over 6 months. In addition to attending weekly classes, participants will track food intake, exercise, and weight. Participants will share online tracking diaries with the group facilitator who will offer individualized feedback on individual progress.~Twelve cooking classes will be run every other week after the in-person weight loss meetings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Demonstrations - Cooking
Description: The Demonstrations group will receive the exact same behavioral weight loss intervention as the cooking group. The only difference is that this group will attend cooking demonstrations as opposed to actively cooking.
Study: NCT03458325

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Furoscix Infusor
Description: Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.
Study: NCT00840177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: 12 mg/m2/day given intravenously over 10-15 minutes on days 4-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin sodium
Description: 1,280 mg/day given orally on days 1-8
Study: NCT01159275

Intervention type: DRUG
Group type: OTHER
Intervention: Generic LPV/r and Aluvia (pharmacokinetics)
Description: Generic LPV/r 200/50 mg BID 12 hr PK then cross over to Pediatric Aluvia 200/50 mg BID

Intervention type: DRUG
Group type: OTHER
Intervention: Aluvia and Generic LPV/r (pharmacokinetics)
Description: First Pediatric Aluvia® 200/50 mg BID, then cross over to Generic LPV/r 200/50 mg BID
Study: NCT02612233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin or Duloxetine or Placebo
Description: This is a randomized, double blind placebo controlled trial with a head-to-head comparison of duloxetine vs pregabalin vs placebo over-encapsulated to prevent unblinding of treatment arm
Study: NCT02378961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily with food
Study: NCT02612233

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin or Duloxetine or Placebo
Description: This is a randomized, double blind placebo controlled trial with a head-to-head comparison of duloxetine vs pregabalin vs placebo over-encapsulated to prevent unblinding of treatment arm
Study: NCT02378961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily with food
Study: NCT03261908

Intervention type: GENETIC
Intervention: detection of genotype
Description: detection of genotype by next generation sequencing

Intervention type: GENETIC
Intervention: detection of genotype
Description: detection of genotype by next generation sequencing
Study: NCT04078126

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BFF
Description: Treatment with budesonide and formoterol furmate MDI (metered-dose inhaler)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbuhaler
Description: Treatment with budesonide and formoterol furmate DPI (dry-powder inhaler)
Study: NCT01727466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facing Your Fears
Description: FYF is a group cognitive behavior therapy that includes parent and child participation. Groups meet weekly for 1 1/2 hours duration, for 14 consecutive weeks.
Study: NCT01020136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
Study: NCT04227236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-based virtual facilitator training for Making Proud Choices
Description: Participants complete the Making Proud Choices (MPC) facilitator training using an e-based virtual trainer on a computer. Making Proud Choices! (MPC) is an evidence-based pregnancy and HIV/STI risk-reduction program for youth. The facilitator training prepares educators to effectively deliver the MPC curriculum.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person facilitator training for Making Proud Choices
Description: Participants complete the Making Proud Choices (MPC) facilitator training using the standard in-person training method. Making Proud Choices! (MPC) is an evidence-based pregnancy and HIV/STI risk-reduction program for youth. The facilitator training prepares educators to effectively deliver the MPC curriculum.
Study: NCT03422367

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: JASPER
Description: JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JASPER
Description: JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
Study: NCT00527865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules containing 10.5 mg of lactose will be supplied as placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules containing 10.5 mg of lactose will be supplied as placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules containing 10.5 mg of lactose will be supplied as placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules containing 10.5 mg of lactose will be supplied as placebo.
Study: NCT03517696

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Membrane sweeping
Description: Participants assigned to membrane sweeping will have an additional exam during their initial evaluation in which the membranes will be separated from the cervix and lower part of the uterus with a finger inserted into the cervical os. This would be done with at least one rotation counterclockwise and one rotation clockwise.
Study: NCT02807168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NT-proBNP (Cardiac Biomarkers)
Study: NCT02447796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24).
Study: NCT03355014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of gemigliptin/metformin HCl sustained release 50/1000mg
Description: Gemigliptin/Metformin HCl extended release 25/500mg 2tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg
Description: Zemiglo 50mg 1 tablet Glucophage XR 2 tablets
Study: NCT01423695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel plus trastuzumab
Description: Weekly paclitaxel (90 mg/m² iv, 12 courses) plus weekly trastuzumab (4mg/kg body weight iv as loading dose, 2 mg/kg iv from week 2 onwards; continued until disease progression)
Study: NCT04614012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treated with hyperimmune plasma
Description: administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5
Study: NCT01142076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xinju Xiaogao Prescription
Description: treatment group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Therapeutic dose of 10%
Study: NCT02327585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A randomized controlled study of Executive Function training for children with ADHD
Description: Children diagnosis of ADHD are randomized to the experimental condition(Executive Function therapy) or waiting group experimental:participants will receive 12 sessions of executive function therapy weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison
Study: NCT04058899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: sedative and might be analgesic drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: agonist antagonist narcotic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: infusion pump
Description: infusion pump for titration of fluid containing drug infusion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: infusion pump
Description: infusion pump for titration of fluid containing drug infusion
Study: NCT00883948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimal (Trophic) Feeding
Description: Upon admission to the ICU, enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full Feeding
Description: Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
Study: NCT04393038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: ABX464 50mg QD for 28 days + Standard of Care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 50mg QD for 28 days + Standard of Care
Study: NCT01389674

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2D-strain echo
Description: 2D-strain-analysis with elevation of the radial and circumferential strain and strain rate parameter(systolic and diastolic)occurs through the echocardiography.~Comparison of the echocardiography and the MRI-vitality data, calculation of a cut out of vision value of a vitality diagnosis with the help of 2D-strain-analysis.
Study: NCT02432781

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drink

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 10% dextrose solution mixed with insulin 16 unit 100 mL/h
Study: NCT03346083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban
Description: Factor Xa inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban
Description: Factor Xa inhibitor.
Study: NCT04399200

Intervention type: DEVICE
Intervention: Treatment according to standard care recommandation
Description: SDB treatment according to standard care recommandation: Continuous Positive Airway Pressure (CPAP), Mandibular Advancement Device, Positionnal Therapy, Adaptive Servo-Ventilation (ASV), Non-Invasive Ventilation (NIV)